Novartis studies show Onbrez® Breezhaler® plus tiotropium is more effective than tiotropium alone in treatment of COPD
"The internationally recognized GOLD guidelines state that combining bronchodilators with different modes of action may provide improved efficacy with no increase in side effects", said the principal investigator Donald A. Mahler, MD, of the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, USA. "These are the first 12-week studies to report on the efficacy of two once-daily bronchodilators given concurrently, and the results confirm that the GOLD recommendation holds true for the use of indacaterol plus tiotropium."
The findings were presented today at the American Thoracic Society (ATS) congress in Denver, Colorado.
Onbrez Breezhaler is the only once-daily long-acting beta-2 agonist (LABA) approved in more than 50 countries, while tiotropium (Spiriva® HandiHaler®*) is a long-acting anti-muscarinic (LAMA), both indicated for the treatment of COPD. The two classes of medicines have different modes of action but both therapies are inhaled to provide bronchodilation, i.e. increased airflow into the patient's lungs.
The INTRUST 1 and 2 studies met their primary endpoints by demonstrating significant improvements in lung function of 130 and 120 mL respectively for Onbrez Breezhaler (150 mcg) plus tiotropium (18 mcg) compared to tiotropium alone after 12 weeks (both p<0.001). Both therapies were given once-daily. Lung function was assessed by measuring patients' forced expiratory volume of breath in one second (FEV1) averaged over eight hours (i.e. FEV1 AUC5 min-8h).
Onbrez Breezhaler plus tiotropium also performed significantly better than tiotropium in improving trough FEV1 (i.e. mean of 23 hrs 10 mins and 23 hrs 45 mins post-dose) at week 12, with the two studies showing differences of 80 and 70 mL compared to tiotropium alone (both p<0.001). The changes in trough FEV1 from baseline at week 12 were 230 mL and 190 mL for indacaterol plus tiotropium, and 150 mL and 110 mL for tiotropium alone. In both studies the reduction in use of rescue medication (albuterol) was numerically greater with Onbrez Breezhaler plus tiotropium than with tiotropium alone.
"Previous studies have demonstrated the safety and efficacy profile of Onbrez Breezhaler as monotherapy in COPD, and the latest results indicate that it may have even greater therapeutic potential when combined with another leading class of treatment," said Trevor Mundel, MD, Global Head of Development at Novartis Pharma AG. "These studies add to the comprehensive data supporting Onbrez Breezhaler as an effective treatment for COPD with a good overall safety profile."
INTRUST 1 and 2 were matching 12-week randomized, double-blind Phase III studies involving 1,134 and 1,142 patients respectively with moderate-to-severe COPD (as defined by the GOLD 2007 criteria). One group of patients received Onbrez Breezhaler 150 mcg once-daily, while the other group received placebo. All patients concurrently received open-label tiotropium 18 mcg once-daily.
Indacaterol, formerly known as QAB149, is approved at 150 and 300 mcg once-daily doses for the treatment of COPD under the brand name Onbrez Breezhaler. It was first approved in November 2009 in the European Union, and is now available in more than 15 European countries with additional launches planned during 2011.
QAB149 is not approved in the US, where the Food and Drug Administration (FDA) is due to complete its regulatory review by July 2011. If approved in the US, the proposed trade name will be Arcapta(TM) Neohaler(TM).
COPD is a progressive, life-threatening disease associated with tobacco smoking, air pollution or occupational exposure, which causes obstruction of airflow in the lungs resulting in debilitating bouts of breathlessness. COPD affects 210 million people worldwide and is projected to be the third leading cause of death by 2020. Although often considered a disease of the elderly, research has shown that a majority of COPD patients are under the age of 65 when they are likely to be at the peak of their earning power and family responsibilities.